Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

New Single Step ELISA Kits Available for Multiple Analytes

By BiotechDaily International staff writers
Posted on 11 Sep 2013
A new line of ELISA kits with a universal simplified protocol is now available for biotech and life science researchers.

The Abcam plc. (Cambridge, United Kingdom) line of SimpleStep ELISA kits currently comprise kits for the detection of more than 35 molecules ranging from interleukins and interferons to tumor markers.

Abcam states that the new single wash, colorimetric sandwich ELISA kits have a greatly simplified protocol when compared to standard multistep ELISAs, providing significant timesaving and ease of use. This is accomplished by employing a labeled capture and detection antibody which, "immunocapture" the specific analyte from the sample solution. This entire complex (capture antibody/protein/detection antibody) is in turn immobilized in the well of the microtiter plate via the immunoaffinity of an anti-tag antibody coated in the microplate well.

The unified operational protocol calls for a single one-hour incubation at room temperature and a single wash step. Furthermore, the new SimpleStep platform requires no specific training or new instrumentation.

James Murray, general manager of Abcam, said, “Abcam is continually in touch with researchers to anticipate the latest research trends and developments, so that we can continue to meet their needs worldwide. We are excited to see how SimpleStep ELISA kits will help to increase the pace of scientific discoveries.”

Related Links:
Abcam plc.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.